

Seoyoung C Kim, Scd

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3601043/seoyoung-c-kim-scd-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

179
papers

5,241
citations

40
h-index

66
g-index

200
ext. papers

6,832
ext. citations

5.5
avg, IF

6.32
L-index

#	Paper	IF	Citations
179	Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. <i>Arthritis Care and Research</i> , 2010 , 62, 170-80	4.7	320
178	Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 1729-37	6.3	171
177	2020 American College of Rheumatology Guideline for the Management of Gout. <i>Arthritis Care and Research</i> , 2020 , 72, 744-760	4.7	157
176	Validation of rheumatoid arthritis diagnoses in health care utilization data. <i>Arthritis Research and Therapy</i> , 2011 , 13, R32	5.7	145
175	Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2010 , 12, R154	5.7	145
174	Active-comparator design and new-user design in observational studies. <i>Nature Reviews Rheumatology</i> , 2015 , 11, 437-41	8.1	125
173	Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1577-85	9.5	123
172	Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1154-1164	9.5	119
171	Tumor necrosis factor blockade and the risk of viral infection. <i>Nature Reviews Rheumatology</i> , 2010 , 6, 165-74	8.1	113
170	Patterns and predictors of persistent opioid use following hip or knee arthroplasty. <i>Osteoarthritis and Cartilage</i> , 2017 , 25, 1399-1406	6.2	98
169	Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. <i>BMJ, The</i> , 2018 , 360, k119	5.9	93
168	Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 456-464	2.4	87
167	Fracture Risk After Bariatric Surgery: Roux-en-Y Gastric Bypass Versus Adjustable Gastric Banding. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 1229-1236	6.3	85
166	2020 American College of Rheumatology Guideline for the Management of Gout. <i>Arthritis and Rheumatology</i> , 2020 , 72, 879-895	9.5	82
165	Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1674-9	2.4	82
164	Use of osteoporosis medications after hospitalization for hip fracture: a cross-national study. <i>American Journal of Medicine</i> , 2015 , 128, 519-26.e1	2.4	79
163	Sociodemographics and epidemiology of serious infections requiring hospitalization among adults with systemic lupus erythematosus and lupus nephritis, 2000 to 2006. <i>Arthritis Research and Therapy</i> , 2014 , 16, A37	5.7	78

162	Serious infection incidence rates in pediatric systemic lupus erythematosus according to medication use. <i>Arthritis Research and Therapy</i> , 2014 , 16, A39	5.7	78
161	S203. EFFECT OF LONG-ACTING INJECTIONS OF PALIPERIDONE PALMITATE ON CLINICAL AND FUNCTIONAL OUTCOMES IN PATIENTS WITH SCHIZOPHRENIA BASED ON ILLNESS DURATION. <i>Schizophrenia Bulletin</i> , 2020 , 46, S115-S116	1.3	78
160	FRAILITY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND GLP1-RA IN OLDER ADULTS WITH TYPE 2 DIABETES. <i>Innovation in Aging</i> , 2019 , 3, S582-S582	0.1	78
159	S156. FRONTO-STRIATAL FUNCTIONAL CONNECTIVITY AND STRIATAL DOPAMINE CAPACITY IN TREATMENT-RESPONSIVE AND REFRACTORY SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2018 , 44, S386-S386	1.3	78
158	Impact of the U.S. Food and Drug Administration's Safety-Related Announcements on the Use of Bisphosphonates After Hip Fracture. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 1536-40	6.3	76
157	Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1360-7	2.4	74
156	Bisphosphonates and risk of cardiovascular events: a meta-analysis. <i>PLoS ONE</i> , 2015 , 10, e0122646	3.7	72
155	Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study. <i>Arthritis Care and Research</i> , 2013 , 65, 578-84	4.7	69
154	Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1968-75	2.4	68
153	Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study. <i>Circulation</i> , 2018 , 138, 1116-1126	16.7	68
152	Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2017 , 10, 123-139	3.4	64
151	Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 993-1001	6.3	63
150	Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study. <i>Annals of Internal Medicine</i> , 2019 , 170, 155-163	8	59
149	Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study. <i>Arthritis and Rheumatology</i> , 2019 , 71, 892-900	9.5	59
148	Antibiotic Use in Children - A Cross-National Analysis of 6 Countries. <i>Journal of Pediatrics</i> , 2017 , 182, 239-244.e1	3.6	58
147	Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. <i>American Journal of Medicine</i> , 2015 , 128, 653.e7-653.e16	2.4	58
146	Risk of venous thromboembolism in patients with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2013 , 65, 1600-7	4.7	57
145	Gout: a review of nonmodifiable and modifiable risk factors. <i>Rheumatic Disease Clinics of North America</i> , 2014 , 40, 581-604	2.4	56

144	Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 789-96	6.3	47
143	Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications. <i>Arthritis and Rheumatology</i> , 2017 , 69, 387-397	9.5	46
142	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1592-1600	2.4	45
141	Cardiovascular Risks of Probenecid Versus Allopurinol in Older Patients With Gout. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 994-1004	15.1	43
140	Association of Osteoporosis Medication Use After Hip Fracture With Prevention of Subsequent Nonvertebral Fractures: An Instrumental Variable Analysis. <i>JAMA Network Open</i> , 2018 , 1, e180826	10.4	40
139	Gout, Hyperuricemia, and Crystal-Associated Disease Network Consensus Statement Regarding Labels and Definitions for Disease Elements in Gout. <i>Arthritis Care and Research</i> , 2019 , 71, 427-434	4.7	39
138	Bioequivalence of Biosimilar Tumor Necrosis Factor Inhibitors Compared With Their Reference Biologics: A Systematic Review. <i>Annals of Internal Medicine</i> , 2016 , 165, 565-574	8	39
137	Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2004-10	9.5	38
136	Risk of incident diabetes in patients with gout: a cohort study. <i>Arthritis and Rheumatology</i> , 2015 , 67, 273-89	6.9	38
135	Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	37
134	Identification of smoking using Medicare data—a validation study of claims-based algorithms. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 472-5	2.6	37
133	Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study. <i>BMJ, The</i> , 2017 , 356, j895	5.9	35
132	Geographic patterns in patient demographics and insulin use in 18 countries, a global perspective from the multinational observational study assessing insulin use: understanding the challenges associated with progression of therapy (MOSAIC). <i>BMC Endocrine Disorders</i> , 2015 , 15, 46	3.3	33
131	Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. <i>Acta Diabetologica</i> , 2014 , 51, 1015-23	3.9	33
130	Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis. <i>JAMA Dermatology</i> , 2019 , 155, 1142-1152	5.1	32
129	Shift From Adalimumab Originator to Biosimilars in Denmark. <i>JAMA Internal Medicine</i> , 2020 , 180, 902-903	1.5	32
128	Association of Preoperative Opioid Use With Mortality and Short-term Safety Outcomes After Total Knee Replacement. <i>JAMA Network Open</i> , 2019 , 2, e198061	10.4	32
127	Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States during 1983-2009. <i>Arthritis Care and Research</i> , 2013 , 65, 1529-33	4.7	30

126	Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 611-617	6.3	29
125	Racial disparities in the risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis as urate-lowering drug adverse events in the United States. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 46, 253-258	5.3	29
124	Risk of incident atrial fibrillation in gout: a cohort study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1473-8	4.9	28
123	Sociodemographic, disease, health system, and contextual factors affecting the initiation of biologic agents in rheumatoid arthritis: a longitudinal study. <i>Arthritis Care and Research</i> , 2014 , 66, 980-9	4.7	28
122	Temporal Trends in Use of Biologic DMARDs for Rheumatoid Arthritis in the United States: A Cohort Study of Publicly and Privately Insured Patients. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017 , 23, 809-814	1.9	26
121	No differences in cancer screening rates in patients with rheumatoid arthritis compared to the general population. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3076-82		26
120	Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV Disease. <i>Journal of Rheumatology</i> , 2018 , 45, 1240-1248	4.1	26
119	Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis. <i>JAMA Dermatology</i> , 2019 , 155, 700-707	5.1	25
118	No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 48, 399-405	5.3	24
117	Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. <i>BMC Medical Research Methodology</i> , 2012 , 12, 180	4.7	24
116	Clinical characteristics and medication uses among fibromyalgia patients newly prescribed amitriptyline, duloxetine, gabapentin, or pregabalin. <i>Arthritis Care and Research</i> , 2013 , 65, 1813-9	4.7	24
115	Fracture Risk After Roux-en-Y Gastric Bypass vs Adjustable Gastric Banding Among Medicare Beneficiaries. <i>JAMA Surgery</i> , 2019 , 154, 746-753	5.4	23
114	Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study. <i>Arthritis Care and Research</i> , 2015 , 67, 457-66	4.7	23
113	Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017 , 19, 159	5.7	23
112	The risk of atrial fibrillation in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1091-5	2.4	23
111	Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. <i>Lancet Rheumatology</i> , 2020 , 2, e84-e98	14.2	22
110	Identification of monosodium urate crystal deposits in patients with asymptomatic hyperuricemia using dual-energy CT. <i>RMD Open</i> , 2018 , 4, e000593	5.9	22
109	Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. <i>American Journal of Medicine</i> , 2015 , 128, 539.e7-17	2.4	21

108	Racial/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1187-1193	2.4	21
107	Clinical and health care use characteristics of patients newly starting allopurinol, febuxostat, and colchicine for the treatment of gout. <i>Arthritis Care and Research</i> , 2013 , 65, 2008-14	4.7	21
106	An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout. <i>PLoS ONE</i> , 2018 , 13, e0193622	3.7	21
105	Gout and Risk of Fracture in Women: A Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2017 , 69, 422-428	9.5	20
104	Bisphosphonates and risk of atrial fibrillation: a meta-analysis. <i>Arthritis Research and Therapy</i> , 2010 , 12, R30	5.7	20
103	Comparative Fracture Risks Among United States Medicaid Enrollees With and Those Without Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1141-1146	9.5	19
102	Association of Geography and Access to Health Care Providers With Long-Term Prescription Opioid Use in Medicare Patients With Severe Osteoarthritis: A Cohort Study. <i>Arthritis and Rheumatology</i> , 2019 , 71, 712-721	9.5	18
101	Gout and the Risk of Non-vertebral Fracture. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 230-236	6.3	18
100	Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1183-9	9.5	18
99	Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study. <i>Rheumatology</i> , 2019 , 58, 2122-2129	3.9	17
98	Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 222-228	5.3	17
97	Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis. <i>JAMA Internal Medicine</i> , 2019 , 179, 741-749	11.5	16
96	Validation of claims-based algorithms for identification of high-grade cervical dysplasia and cervical cancer. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 1239-44	2.6	16
95	Risk of Hospitalized Infection and Initiation of Abatacept Versus Tumor Necrosis Factor Inhibitors Among Patients With Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study. <i>Arthritis Care and Research</i> , 2020 , 72, 9-17	4.7	16
94	Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2018 , 20, 42	4.9	16
93	The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [¹¹ C]-raclopride PET study with aripiprazole. <i>Translational Psychiatry</i> , 2018 , 8, 87	8.6	14
92	Relationships between driving distance, rheumatoid arthritis diagnosis, and disease-modifying antirheumatic drug receipt. <i>Arthritis Care and Research</i> , 2014 , 66, 1634-43	4.7	14
91	Tumor Necrosis Factor Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis. <i>Epidemiology</i> , 2016 , 27, 414-22	3.1	14

90	An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score. <i>Arthritis Research and Therapy</i> , 2015 , 17, 83	5.7	12
89	Validation of claims-based algorithms for gout flares. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 820-6	2.6	12
88	Use of prescription opioids among patients with rheumatic diseases compared to patients with hypertension in the USA: a retrospective cohort study. <i>BMJ Open</i> , 2019 , 9, e027495	3	12
87	Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population. <i>Journal of General Internal Medicine</i> , 2015 , 30, 1633-8	4	11
86	Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy. <i>Circulation</i> , 2021 , 143, 770-779	16.7	11
85	Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Rheumatoid Arthritis: A Cohort Study. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2106-13	9.5	11
84	Patterns of health care utilization related to initiation of amitriptyline, duloxetine, gabapentin, or pregabalin in fibromyalgia. <i>Arthritis Research and Therapy</i> , 2015 , 17, 18	5.7	10
83	Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1036-1038	9.5	10
82	Risk of Inflammatory Arthritis After a New Diagnosis of Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2020 , 156, 342-345	5.1	10
81	Association between inflammation and systolic blood pressure in RA compared to patients without RA. <i>Arthritis Research and Therapy</i> , 2018 , 20, 107	5.7	10
80	Association of Medicare's Bundled Payment Reform With Changes in Use of Vitamin D Among Patients Receiving Maintenance Hemodialysis: An Interrupted Time-Series Analysis. <i>American Journal of Kidney Diseases</i> , 2018 , 72, 178-187	7.4	10
79	Human papillomavirus vaccine uptake among individuals with systemic inflammatory diseases. <i>PLoS ONE</i> , 2015 , 10, e0117620	3.7	10
78	The relationship between grey matter volume and striatal dopamine function in psychosis: a multimodal F-DOPA PET and voxel-based morphometry study. <i>Molecular Psychiatry</i> , 2021 , 26, 1332-1345 ^{15.1}	15.1	10
77	Brief Report: Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1076-9	9.5	9
76	Predictors of stopping and starting disease-modifying antirheumatic drugs for rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2014 , 66, 1152-8	4.7	9
75	Risk of exacerbation of pulmonary comorbidities in patients with rheumatoid arthritis after initiation of abatacept versus TNF inhibitors: A cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 401-408	5.3	9
74	Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015. <i>Arthritis Care and Research</i> , 2018 , 70, 791-796	4.7	9
73	Optimum Designs for Large Database Research in Musculoskeletal Pain Management. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020 , 102 Suppl 1, 54-58	5.6	8

72	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2021 , 174, 1528-1541	8	8
71	Practice Pattern of Hepatitis B Testing in Rheumatoid Arthritis Patients: A Cross-National Comparison Between the US and Taiwan. <i>Arthritis Care and Research</i> , 2018 , 70, 30-38	4.7	7
70	Accuracy of identifying neutropenia diagnoses in outpatient claims data. <i>Pharmacoepidemiology and Drug Safety</i> , 2011 , 20, 709-13	2.6	7
69	Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020 ,	6.9	7
68	Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. <i>Rheumatology</i> , 2021 ,	3.9	7
67	Frontostriatal functional connectivity and striatal dopamine synthesis capacity in schizophrenia in terms of antipsychotic responsiveness: an [F]DOPA PET and fMRI study. <i>Psychological Medicine</i> , 2019 , 49, 2533-2542	6.9	7
66	Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 300-311	4.5	7
65	Validation of claims-based algorithms to identify interstitial lung disease in patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 592-597	5.3	6
64	Methodological Challenges in Conducting Large-Scale Real-World Data Analyses on Opioid Use in Musculoskeletal Disorders. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020 , 102 Suppl 1, 10-14	5.6	6
63	Risk of human papillomavirus infection in women with rheumatic disease: cervical cancer screening and prevention. <i>Rheumatology</i> , 2018 , 57, v26-v33	3.9	6
62	Cardiovascular Safety of Urate Lowering Therapies. <i>Current Rheumatology Reports</i> , 2019 , 21, 48	4.9	6
61	Tofacitinib and risk of cardiovascular outcomes: results from the Safety of Tofacitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	6
60	Risk of Incident Type 2 Diabetes Mellitus Among Patients With Rheumatoid Arthritis: A Population-Based Cohort Study. <i>Arthritis Care and Research</i> , 2020 , 72, 1248-1256	4.7	6
59	Dopamine dysregulation in psychotic relapse after antipsychotic discontinuation: an [F]DOPA and [C]raclopride PET study in first-episode psychosis. <i>Molecular Psychiatry</i> , 2021 , 26, 3476-3488	15.1	6
58	Risk of Hospitalized Serious Infection After Initiating Ustekinumab or Other Biologics for Psoriasis or Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2021 ,	4.7	6
57	Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients. <i>Rheumatology</i> , 2021 , 60, 3689-3698	3.9	6
56	Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease, a Cohort Study. <i>Diabetes Care</i> , 2021 ,	14.6	6
55	Cardiovascular risk associated with allopurinol vs. benzbromarone in patients with gout. <i>European Heart Journal</i> , 2021 , 42, 4578-4588	9.5	6

54	Cross-National Variation in Glycemic Control and Diabetes-Related Distress Among East Asian Patients Using Insulin: Results from the MOSAIC Study. <i>Diabetes Therapy</i> , 2016 , 7, 349-60	3.6	5
53	Assessment of body water distribution in patients with sepsis during fluid resuscitation using multi-frequency direct segmental bioelectrical impedance analysis. <i>Clinical Nutrition</i> , 2020 , 39, 1826-1833	5.9	5
52	Fracture Risk After Initiation of Use of Canagliflozin. <i>Annals of Internal Medicine</i> , 2019 , 171, 80	8	5
51	Methodologic considerations for noninterventional studies of switching from reference biologic to biosimilars. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 757-769	2.6	5
50	Risk of Incident Atrial Fibrillation With Zoledronic Acid Versus Denosumab: A Propensity Score-Matched Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 52-60	6.3	5
49	Increased Risk of Psychopathological Abnormalities in Subjects With Unilateral Hearing Loss: A Cross-Sectional Study. <i>Clinical and Experimental Otorhinolaryngology</i> , 2021 , 14, 82-87	3.4	5
48	Assessment of coronary vascular function with cardiac PET in relation to serum uric acid. <i>PLoS ONE</i> , 2018 , 13, e0192788	3.7	4
47	Patterns of bisphosphonates utilization in patients under age 45 in a large cohort of commercial insurance beneficiaries in the United States. <i>PLoS ONE</i> , 2015 , 10, e0115091	3.7	4
46	Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. <i>JAMA Network Open</i> , 2021 , 4, e2130762	10.4	4
45	Trends in Utilization of Urate-Lowering Therapies Following the US Food and Drug Administration's Boxed Warning on Febuxostat. <i>Arthritis and Rheumatology</i> , 2021 , 73, 542-543	9.5	4
44	Asymptomatic hyperuricemia and coronary flow reserve in patients with metabolic syndrome. <i>BMC Rheumatology</i> , 2018 , 2, 17	2.9	4
43	A tool for empirical equipoise assessment in multigroup comparative effectiveness research. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 934-941	2.6	3
42	Comparative Risk of Diabetes Mellitus in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease-Modifying Drugs: A Cohort Study. <i>ACR Open Rheumatology</i> , 2020 , 2, 222-231	3.5	3
41	Mapping from the International Classification of Diseases (ICD) 9th to 10th Revision for Research in Biologics and Biosimilars Using Administrative Healthcare Data. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 770-777	2.6	3
40	Towards defining the safer use of opioids in rheumatology. <i>Nature Reviews Rheumatology</i> , 2020 , 16, 71-72	8.1	3
39	Validation of claims-based algorithms for psoriatic arthritis. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 404-408	2.6	3
38	Use of biologic or targeted-synthetic disease-modifying anti-rheumatic drugs and risk of diabetes treatment intensification in patients with rheumatoid arthritis and diabetes mellitus. <i>Rheumatology Advances in Practice</i> , 2020 , 4, rkaa027	1.1	3
37	Predicting Response to Tocilizumab Monotherapy in Rheumatoid Arthritis: A Real-world Data Analysis Using Machine Learning. <i>Journal of Rheumatology</i> , 2021 , 48, 1364-1370	4.1	3

36	Risk of Serious Infection Among Initiators of Tumor Necrosis Factor Inhibitors Plus Methotrexate Versus Triple Therapy for Rheumatoid Arthritis: A Cohort Study. <i>Arthritis Care and Research</i> , 2020 , 72, 1383-1391	4.7	3
35	Effects of Long-Acting Injectable Paliperidone Palmitate on Clinical and Functional Outcomes in Patients With Schizophrenia Based on Illness Duration. <i>Journal of Clinical Psychiatry</i> , 2021 , 82,	4.6	3
34	Validation of obesity-related diagnosis codes in claims data. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2623-2631	6.7	3
33	Accuracy of identifying diagnosis of moderate to severe chronic kidney disease in administrative claims data.. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 ,	2.6	3
32	Predicting Remission Among Patients With Rheumatoid Arthritis Starting Tocilizumab Monotherapy: Model Derivation and Remission Score Development. <i>ACR Open Rheumatology</i> , 2020 , 2, 65-73	3.5	2
31	Assessment for Perioperative Hyperglycemia Prior to Total Joint Replacement in Patients With and Without Diabetes. <i>JAMA Network Open</i> , 2019 , 2, e1910589	10.4	2
30	Behavioral and clinical factors associated with self-reported abnormal Papanicolaou tests in rheumatoid arthritis. <i>Journal of Women's Health</i> , 2014 , 23, 771-6	3	2
29	Relationship of Change in Plasma Clozapine/N-desmethylclozapine Ratio with Cognitive Performance in Patients with Schizophrenia. <i>Psychiatry Investigation</i> , 2020 , 17, 1158-1165	3.1	2
28	Risk of Uveitis in Patients With Inflammatory Bowel Disease on Immunosuppressive Drug Therapy. <i>Crohn's & Colitis</i> 360 , 2020 , 2,	1.4	2
27	Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol. <i>Journal of the American Heart Association</i> , 2021 , 10, e020045	6	2
26	Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases. <i>JAMA Dermatology</i> , 2021 , 157, 805-816	5.1	2
25	Real-world patterns of pegloticase use for treatment of gout: descriptive multidatabase cohort study. <i>BMJ Open</i> , 2020 , 10, e041167	3	1
24	Risk of Venous Thromboembolism Associated With Methotrexate Versus Hydroxychloroquine for Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1242-1250	5.3	1
23	Comparative risks of cardiovascular disease events among SLE patients receiving immunosuppressive medications. <i>Rheumatology</i> , 2021 , 60, 3789-3798	3.9	1
22	Tuberculosis risk with biologics by screening-guided preventive strategy in rheumatoid arthritis under intermediate tuberculosis burden. <i>Rheumatology</i> , 2021 , 60, 2755-2764	3.9	1
21	Validation of claims-based algorithms to identify patients with psoriasis. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 868-874	2.6	1
20	Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020. <i>Journal of General Internal Medicine</i> , 2021 , 1	4	1
19	Potential confounding in colchicine and cardiovascular disease study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e27	2.4	1

18	Response to: Effects of colchicine on risk of cardiovascular events among patients with gout: as evidence accrues, is it time for a randomized trial? Sby Giannopoulos and Deftereos. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e29	2.4	1
17	Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021 , 27, 1106-1117	7.9	1
16	Identification of Acute Giant Cell Arteritis in Real-World Data Using Administrative Claims-Based Algorithms. <i>ACR Open Rheumatology</i> , 2021 , 3, 72-78	3.5	1
15	Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.. <i>Cardiovascular Diabetology</i> , 2022 , 21, 47	8.7	1
14	Risk of Cataract Surgery and Age-Related Macular Degeneration After Initiation of Denosumab vs Zoledronic Acid for Osteoporosis: A Multi-Database Cohort Study. <i>Drugs and Aging</i> , 2020 , 37, 311-320	4.7	0
13	Pharmacotherapy: comparative safety of nonsteroidal anti-inflammatory drugs. <i>Nature Reviews Cardiology</i> , 2011 , 8, 193-5	14.8	0
12	Medication Burden and Prescribing Patterns in Patients on Hemodialysis in the USA, 2013-2017. <i>American Journal of Nephrology</i> , 2021 , 1-10	4.6	0
11	The Patterns of Use of Medications for Inflammatory Bowel Disease During Pregnancy in the US and Sweden Are Changing. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1427-1434	4.5	0
10	Risk of Diabetes Mellitus in Patients with Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2020 , 47, 1405-1408	4.1	0
9	Temporal Trends in Prescribing of Bone-Directed Therapies in the United States, 2009-2020. <i>Journal of the Endocrine Society</i> , 2021 , 5, A250-A250	0.4	0
8	FRAILITY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND DPP4I IN OLDER ADULTS WITH TYPE 2 DIABETES. <i>Innovation in Aging</i> , 2019 , 3, S582-S582	0.1	0
7	The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy. <i>Arthritis Research and Therapy</i> , 2021 , 23, 26	5.7	0
6	Comparative Risk of Nonvertebral Fractures Among Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs. <i>ACR Open Rheumatology</i> , 2021 , 3, 531-539	3.5	0
5	Alendronate and Hip Fracture in Patients Using Glucocorticoids. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 1711-1712	27.4	
4	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.. <i>Annals of Internal Medicine</i> , 2022 , 175, W4	8	
3	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.. <i>Annals of Internal Medicine</i> , 2022 , 175, W4-W5	8	
2	Associations of Clozapine Use With Psychosocial Functioning and Quality of Life in Patients With Schizophrenia: A Community-Based Cross-Sectional Study. <i>Psychiatry Investigation</i> , 2021 , 18, 968-976	3.1	
1	Change in Cognitive Function after Antipsychotics Treatment : A Pilot Study of Long-Acting Injectable versus Oral Form. <i>Korean Journal of Schizophrenia Research</i> , 2018 , 21, 74	0.7	

